A Clinical Study of FT1 in Patients With Short Bowel Syndrome

The goal of this clinical trial is to learn if FT1 is safe and works to treat short bowel syndrome (SBS) in adults. It will also learn about the PK/PD profile of FT1. Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and effective in patients with SBS. Participants will * Receive multiple injections of FT1 or placebo according to weight. * Visit the clinic for assessment.

NCT Number	NCT07704047
Lead Sponsor	Chongqing Peg-Bio Biopharm Co., Ltd.
Conditions	Short Bowel Syndrome, SBS
Enrollment	8 participants
Start Date	2026-08-30
Primary Completion	2027-04-15 (estimated)
Study Completion	2027-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-15